Organization | University of Melbourne

University of Melbourne Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Melbourne Australia (1853)

Organization Overview

First Clinical Trial

1995

NCT00002678

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Alternative names

3. Department of Medicine, University of Melbourne, Royal Melbourne Hospital, Parkville Victoria Australia | Austin and Repatriation Hospital | Austin Health, University of Melbourne | Austin Hospital and University of Melbourne | Austin Hospital, Melbourne Australia | Austin Hospital & University of Melbourne | Austin Hospital, University of Melbourne | Austin Hospital, VIC, Australia | Austin & Northern Hospitals, University of Melbourne | Australian National University, Canberra, Australia | Centre for Youth Mental Health, University of Melbourne, Australia | Department of Neurology, Royal Melbourne Hospital | Director Department of Nephrology, The Royal Melbourne Hospital | Director of Anaesthesia, Royal Melbourne Hospital | Director of Clinical Haematology, Austin Hospital, Australia | Intensive Care Unit Research Department, Royal Melbourne Hospital | Intensive Care Unit, Royal Melbourne Hospital | Melbourne Children's Campus (incorporating The Royal Children's Hospital, Murdoch Children's Research Institute, the University of Melbourne Department of Paediatrics) | Melbourne Health and University of Melbourne | Melbourne Health Dept of Neurology & The University of Melbourne Dept of Medicine | Melbourne Heart Centre, Royal Melbourne Hospital | Melbourne Sexual Health Centre | Menzies School of Health Research and University of Melbourne | Murdoch Children Research Institute/Royal Children Hospital, Melbourne | Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne | Murdoch Children's Research Institute, Vicotria, Australia | ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry, University of Melbourne | ORYGEN Research Centre, University of Melbourne | ORYGEN Youth Health, University of Melbourne, Department of Psychiatry | Peter Doherty Institute for Infection and Immunity, The University of Melbourne | Royal Children's Hospital | Royal Children's Hospital, Brisbane, Herston, QLD, Australia | Royal Children's Hospital, Brisbane, QLD, Australia | Royal Children's Hospital, Melbourne | Royal Children's Hospital Melbourne Australia | Royal Children's Hospital Melbourne (Australia) | Royal Children's Hospital, Parkville, Victoria, Australia | Royal Children's Hospital, Queensland Paediatric Infectious Diseases Laboratory | Royal Melbourne Hospital | Royal Melbourne Hospital, Head, Diabetic Foot Unit | Royal Melbourne Hospital, Intensive Care Unit | Royal Victoria Eye and Ear Hospital | Royal Victoria Eye & Ear Hospital, Department of Ophthalmology, University of Melbourne | Royal Victoria Hospital | Royal Victoria Hospital, Canada | Royal Victoria Hospital - Montreal | Royal Victoria Hospital Of Barrie | Royal Victoria Infirmary | Royal Women's Hospital | Royal Womens Hospital Melbourne | Sir James Spence Institute of Child Health at Royal Victoria Infirmary | Stuart Mazzone | The Doherty Institute, University of Melbourne | The Peter Doherty Institute for Infection and Immunity, University of Melbourne | The Royal Children's Hospital Melbourne | The Royal Victoria Hospital | The Royal Victoria Hospital of Barrie | The Royal Women Hospital | The Royal Women's Hospital | The Royal Womens Hospital Melbourne | The Univeristy of Melbourne and Murdoch Childrens Research Institute | The University of Melbourne and Murdoch Childrens Research Institute | The University of Melbourne and The Melbourne Clinic | University of Melbourne | University of Melbourne, Australia | University of Melbourne, Department of Psychiatry, ORYGEN Research Centre | Victorian Comprehensive Cancer Centre

University of Melbourne Report issue

Drugs in Phase 4 Trials (32)

Drugs in Phase 3 Trials (78)

Drugs in Phase 2 Trials (37)

Drugs in Phase 1 Trials (8)

Drugs in Other Trials (18)

Experimental Indications (Clinical Trials, Phases 1-4)

Overview